Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J.

Clin Cancer Res. 2000 Apr;6(4):1365-71.

2.

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH.

J Clin Oncol. 2000 Feb;18(4):927-41.

PMID:
10673536
3.

Bioassays for itraconazole blood levels: an interlaboratory collaborative study.

Odds FC, Dupont B, Rinaldi MG, Stevens DA, Warnock DW, Woestenborghs R.

J Antimicrob Chemother. 1999 May;43(5):723-7.

PMID:
10382898
5.

Pharmacokinetics of lubeluzole (Prosynap) after single intravenous doses in healthy subjects.

Van de Velde V, Crabbe R, Van Peer A, Woestenborghs R, Van Osselaer N, Hantson L, Heykants J.

Int J Clin Pharmacol Ther. 1998 Sep;36(9):490-3.

PMID:
9760010
6.

Determination of the dose proportionality of single intravenous doses (5, 10, and 15 mg) of lubeluzole in healthy volunteers.

Herron J, Lee P, Pesco-Koplowitz L, Gajjar D, Soo YW, Woestenborghs R.

Clin Ther. 1998 Jul-Aug;20(4):682-90.

PMID:
9737828
7.

A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection.

Zhou H, Goldman M, Wu J, Woestenborghs R, Hassell AE, Lee P, Baruch A, Pesco-Koplowitz L, Borum J, Wheat LJ.

J Clin Pharmacol. 1998 Jul;38(7):593-602.

PMID:
9702843
8.

Safety and pharmacokinetics of the neuroprotective drug lubeluzole in patients with ischemic stroke.

De Keyser J, Van de Velde V, Schellens RL, Hantson L, Tritsmans L, Gheuens J, Van Peer A, Woestenborghs R, Franke CL, van Gorp J.

Clin Ther. 1997 Nov-Dec;19(6):1340-51.

PMID:
9444444
9.

Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units.

Vandewoude K, Vogelaers D, Decruyenaere J, Jaqmin P, De Beule K, Van Peer A, Woestenborghs R, Groen K, Colardyn F.

Antimicrob Agents Chemother. 1997 Dec;41(12):2714-8.

10.

Inhibition of pancreaticobiliary secretion by loperamide in humans.

Thimister PW, Hopman WP, van Roermund RF, Willems HL, Rosenbusch G, Woestenborghs R, Jansen JB.

Hepatology. 1997 Aug;26(2):256-61.

PMID:
9252131
11.

Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates.

Snoeck E, Piotrovskij V, Jacqmin P, Van Peer A, Danhof M, Ver Donck K, Woestenborghs R, Van Belle H, Van Bortel L, Van Gool R, Dupont AG, Heykants J.

Br J Clin Pharmacol. 1997 Jun;43(6):603-12.

12.

Risperidone: effects of formulations on oral bioavailability.

Gutierrez R, Lee PI, Huang ML, Woestenborghs R.

Pharmacotherapy. 1997 May-Jun;17(3):599-605.

PMID:
9165565
13.

Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole.

Lefebvre RA, Van Peer A, Woestenborghs R.

Br J Clin Pharmacol. 1997 Mar;43(3):319-22.

14.

Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations.

Snoeck E, Piotrovskij V, Jacqmin P, Lins RL, Van Peer A, Danhof M, Woestenborghs R, Van Gool R, Dupont AG, Heykants J.

Eur J Clin Pharmacol. 1997;53(1):57-63.

PMID:
9349931
15.

Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects.

Cheymol G, Woestenborghs R, Snoeck E, Ianucci R, Le Moing JP, Naditch L, Levron JC, Poirier JM.

Eur J Clin Pharmacol. 1997;51(6):493-8.

PMID:
9112066
16.

The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine.

Snoeck E, Jacqmin P, Van Peer A, Danhof M, Ver Donck K, Van Belle H, Woestenborghs R, Crabbé R, Van Gool R, Dupont A, Heykants J.

Br J Clin Pharmacol. 1996 Nov;42(5):605-13.

17.

The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy.

Hansdóttir V, Woestenborghs R, Nordberg G.

Anesth Analg. 1996 Aug;83(2):401-6.

PMID:
8694326
18.

Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole.

Van de Velde VJ, Van Peer AP, Heykants JJ, Woestenborghs RJ, Van Rooy P, De Beule KL, Cauwenbergh GF.

Pharmacotherapy. 1996 May-Jun;16(3):424-8.

PMID:
8726601
19.

Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole.

De Doncker P, Decroix J, Piérard GE, Roelant D, Woestenborghs R, Jacqmin P, Odds F, Heremans A, Dockx P, Roseeuw D.

Arch Dermatol. 1996 Jan;132(1):34-41.

PMID:
8546481
20.

Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man.

Snoeck E, Van Peer A, Sack M, Horton M, Mannens G, Woestenborghs R, Meibach R, Heykants J.

Psychopharmacology (Berl). 1995 Dec;122(3):223-9.

PMID:
8748391
21.

Linearity of pharmacokinetics and model estimation of sufentanil.

Gepts E, Shafer SL, Camu F, Stanski DR, Woestenborghs R, Van Peer A, Heykants JJ.

Anesthesiology. 1995 Dec;83(6):1194-204.

PMID:
8533912
22.

The pharmacokinetic properties of topical levocabastine. A review.

Heykants J, Van Peer A, Van de Velde V, Snoeck E, Meuldermans W, Woestenborghs R.

Clin Pharmacokinet. 1995 Oct;29(4):221-30. Review.

PMID:
8549024
23.

The cerebrospinal fluid and plasma pharmacokinetics of sufentanil after thoracic or lumbar epidural administration.

Hansdottir V, Woestenborghs R, Nordberg G.

Anesth Analg. 1995 Apr;80(4):724-9.

PMID:
7893025
24.

Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans.

Lavrijsen K, van Dyck D, van Houdt J, Hendrickx J, Monbaliu J, Woestenborghs R, Meuldermans W, Heykants J.

Drug Metab Dispos. 1995 Mar;23(3):354-62.

PMID:
7628301
25.

Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.

Van Beijsterveldt LE, Geerts RJ, Wuyts K, Woestenborghs RJ, Meuldermans WE, Heykants JJ.

Drug Metab Dispos. 1995 Feb;23(2):216-22.

PMID:
7736914
26.

New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs.

Pauwels R, Andries K, Debyser Z, Kukla MJ, Schols D, Breslin HJ, Woestenborghs R, Desmyter J, Janssen MA, De Clercq E, et al.

Antimicrob Agents Chemother. 1994 Dec;38(12):2863-70.

27.

The pharmacokinetics of risperidone in humans: a summary.

Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R.

J Clin Psychiatry. 1994 May;55 Suppl:13-7.

PMID:
7520903
28.

Assay methods for sufentanil in plasma. Radioimmunoassay versus gas chromatography-mass spectrometry.

Woestenborghs RJ, Timmerman PM, Cornelissen ML, Van Rompaey FA, Gepts E, Camu F, Heykants JJ, Stanski DR.

Anesthesiology. 1994 Mar;80(3):666-70.

PMID:
8141462
29.

Pharmacokinetics of orally administered levocabastine in patients with renal insufficiency.

Zazgornik J, Huang ML, Van Peer A, Woestenborghs R, Heykants J, Stephen A.

J Clin Pharmacol. 1993 Dec;33(12):1214-8.

PMID:
7907347
30.

Absorption, metabolism, and excretion of risperidone in humans.

Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J.

Drug Metab Dispos. 1993 Nov-Dec;21(6):1134-41.

PMID:
7507814
31.

Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations.

Hostetler JS, Heykants J, Clemons KV, Woestenborghs R, Hanson LH, Stevens DA.

Antimicrob Agents Chemother. 1993 Oct;37(10):2224-7.

32.

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.

Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH.

Clin Pharmacol Ther. 1993 Sep;54(3):257-68.

PMID:
7690693
33.

Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase.

Pauwels R, Andries K, Debyser Z, Van Daele P, Schols D, Stoffels P, De Vreese K, Woestenborghs R, Vandamme AM, Janssen CG, et al.

Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1711-5.

34.

Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography.

Woestenborghs R, Lorreyne W, Van Rompaey F, Heykants J.

J Chromatogr. 1992 Dec 2;583(2):223-30.

PMID:
1282517
35.

Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro.

Bowden CR, Voina SJ, Woestenborghs R, De Coster R, Heykants J.

J Pharmacol Exp Ther. 1992 Aug;262(2):699-706.

PMID:
1380082
36.

The pharmacokinetics of oral itraconazole in AIDS patients.

Smith D, van de Velde V, Woestenborghs R, Gazzard BG.

J Pharm Pharmacol. 1992 Jul;44(7):618-9.

PMID:
1357148
37.

Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis.

Willemsen M, De Doncker P, Willems J, Woestenborghs R, Van de Velde V, Heykants J, Van Cutsem J, Cauwenbergh G, Roseeuw D.

J Am Acad Dermatol. 1992 May;26(5 Pt 1):731-5.

PMID:
1316389
38.

Dose proportionality study of loperamide following oral administration of loperamide oxide.

Kamali F, Adriaens L, Huang ML, Woestenborghs R, Emanuel M, Rawlins MD.

Eur J Clin Pharmacol. 1992;42(6):693-4.

PMID:
1623916
39.

Single-dose and steady-state pharmacokinetics of sabeluzole in senile dementia of Alzheimer type patients.

De Deyn PP, Van de Velde V, Verslegers W, Saerens J, Pickut BA, Clincke B, Woestenborghs R, Van Peer A.

Eur J Clin Pharmacol. 1992;43(6):661-2.

PMID:
1493851
40.

Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis.

Matthieu L, De Doncker P, Cauwenbergh G, Woestenborghs R, van de Velde V, Janssen PA, Dockx P.

Clin Exp Dermatol. 1991 Sep;16(5):374-6.

PMID:
1665402
41.

The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration.

Hansdottir V, Hedner T, Woestenborghs R, Nordberg G.

Anesthesiology. 1991 Feb;74(2):264-9.

PMID:
1671323
42.

Study of the placental transfer of cisapride in sheep. Plasma levels in the pregnant ewe, the fetus, and the lamb.

Veereman-Wauters G, Monbaliu J, Meuldermans W, Woestenborghs R, Verlinden M, Heykants J, Rudolph CD.

Drug Metab Dispos. 1991 Jan-Feb;19(1):168-72.

PMID:
1673393
43.

Pharmacokinetics of oral antifungals and their clinical implications.

Heykants J, Van Peer A, Lavrijsen K, Meuldermans W, Woestenborghs R, Cauwenbergh G.

Br J Clin Pract Suppl. 1990 Sep;71:50-6. Review.

PMID:
1965419
44.

Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.

Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, et al.

Nature. 1990 Feb 1;343(6257):470-4.

PMID:
1689015
45.

Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers.

Hedner T, Hedner J, Gelin-Friberg A, Huang ML, Van de Poel S, Woestenborghs R, Van Peer A, Heykants J.

Eur J Clin Pharmacol. 1990;38(6):629-31.

PMID:
2373139
46.

On the terrestrial toxicity of the fungicide imazalil (enilconazole) to the earthworm species Eisenia foetida.

Van Leemput L, Swysen E, Woestenborghs R, Michielsen L, Meuldermans W, Heykants J.

Ecotoxicol Environ Saf. 1989 Dec;18(3):313-20.

PMID:
2612423
47.

Deuterated ritanserin analysis by gas chromatography/mass spectrometry: a sensitive technique to study human ritanserin pharmacokinetics.

Timmerman P, Woestenborghs R, Lenoir H, Heykants J.

Biomed Environ Mass Spectrom. 1989 Jul;18(7):498-502.

PMID:
2505878
48.

Pharmacokinetics of alfentanil during and after a fixed rate infusion.

Van Beem H, Van Peer A, Gasparini R, Woestenborghs R, Heykants J, Noorduin H, Van Egmond J, Crul J.

Br J Anaesth. 1989 Jun;62(6):610-5.

49.

Itraconazole versus ketoconazole for the prophylaxis of fungal infection in neutropenic children: results of two consecutive nonrandomized studies.

Ninane J, Sluysmans T, Vermylen C, De Beule K, Woestenborghs R, Cauwenbergh G, Cornu G.

Pediatr Hematol Oncol. 1989;6(4):349-53.

PMID:
2561916
50.

The clinical pharmacokinetics of itraconazole: an overview.

Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, Cauwenbergh G.

Mycoses. 1989;32 Suppl 1:67-87. Review.

PMID:
2561187

Supplemental Content

Loading ...
Support Center